论文部分内容阅读
ARDS自1967年首次报道以来,已在人类进行了大量研究。其低氧血症、肺顺应性降低和肺浸润等特点已被充分认识。尽管呼吸支持疗法不断改进,病死率仍在50%以上。目前支持疗法仍然是ARDS病人的主要治疗方法之一,其目的在于缓解呼吸衰竭,纠正低氧血症和治疗先驱疾病。缓解呼衰为治疗先驱病争取时间,治疗先驱病为恢复有效气体交换争取可能性,二者兼顾不可偏废。一、纠正低氧血症:低氧血症是肺泡陷闭、通气不足、通气血流比例失调、肺内静动脉分流、等的后果。因此治疗的根本措施是促进肺泡扩张和积极氧
Since ARDS was first reported in 1967, a great deal of research has been conducted in humans. Its hypoxemia, reduced lung compliance and pulmonary infiltration and other characteristics have been fully recognized. Although respiratory support therapies continue to improve, the case fatality rate is still above 50%. Currently, supportive care remains one of the major treatments for patients with ARDS, with the aim of relieving respiratory failure, correcting hypoxemia and treating pioneer illnesses. Alleviating respiratory failure for the treatment of pioneer race time, the treatment of pioneer disease for the restoration of effective gas exchange for the possibility of both can not be neglected. First, to correct hypoxemia: hypoxemia is alveolar collapse, hypoventilation, ventilation and blood flow imbalance, pulmonary shunt, and so the consequences. Therefore, the fundamental treatment is to promote alveolar expansion and active oxygen